Role of booster dose on antibody titer after recombinant hepatitis B vaccination

Journal of Medicine

Volumn 10, Issue 2, 2009, Pages 67-76

  Ahad, Md Abdul ^a   Alim, Md Abdul ^a   Guho, Abhijit ^a   Islam, Quazi Tarikul ^a   Azad, Khan Abul Kalam ^b  

^a RAJSHAHI MEDICAL COLLEGE   (Bangladesh)

^b DHAKA MEDICAL COLLEGE   (Bangladesh)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; RECOMBINANT HEPATITIS B VACCINE;

ADOLESCENT; ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BOOSTER DOSE; DRUG DOSE REGIMEN; DRUG RESPONSE; FEMALE; HEPATITIS B; HUMAN; IMMUNE RESPONSE; INFANT; MAJOR CLINICAL STUDY; MALE; PROTECTION; SCREENING; SEROCONVERSION; VACCINATION;

EID: 77953402917     PISSN: 19979797     EISSN: None     Source Type: Journal    
DOI: 10.3329/jom.v10i2.2817     Document Type: Article

References (39)

1. WHO. Hepatitis B: World Health Organization Fact Sheet 204, 2000.
2. Lee WM. Hepatitis B infection. N Engl J Med 1997; 337: 1733 - 1745.
3. Mahoney FJ. Update on diagnosis, management, and prevention of hepatitis B virus infection. Clin Microbiol Rev 1999; 12: 351 - 366.
4. Margolis HS, Alter MJ, Hadler SC. Hepatitis B: evolving epidemiology and implications for control. Semin Liver Dis 1991;11: 84 - 92.
5. Alter M. Epidemiology of hepatitis B in Europe and worldwide. J Hepatol 2003;39:S64-S69.
6. Toukan A. Strategy for the control of hepatitis B virus infection in the Middle East and North Africa. Vaccine 1990; 8(suppl): S117 - S121.
7. McQuillan GM, Townsend TR, Fields HA, et al. Seroepidemiology of hepatitis B virus infection in the United States. Am J Med 1989; 87(suppl 3A): 5S - 10S.
8. Gibney L, Saquib N, Metzger J, et al. Human immunodeficiency virus hepatitis B, C and D in Bangladesh trucking industry; prevalence and risk factors. Int J Epidemiol 2001; 30: 878 - 884.
9. De Francisco A, Hall AJ, Alam N, Hawkes S, Azim T. Hepatitis B infection in Bangladeshi mothers and infants. Southeast Asian J Trop Med Public Health 1999; 30: 296 - 298.
10. Rahman R, Amanullah, Sattar H, et al. Seroepidemiological study of hepatitis B virus infection in a village. Bangladesh Med Res Counc Bull 1997;23(2):38-41.
11. Rumi MA, Begum K, Hasan SM, et al. Detection of hepatitis B surface antigen in pregnant women attending a public hospital for delivery: implication for vaccination strategy in Bangladesh. Am J Trop Med Hyg 1998; 59(2): 318-22.
12. Khan M, Zaki KMJ, Ahmed KU. Clinical profile: Prognostic index in hepatocellularcarcinoma. Bangladesh Med Res Coun Bull. 1991; XVII: 49-62.
13. Bancroft WH, Snitbhan R, Scott RM, Tingpalapong M, Watson WT, Tanticharoenyos P. et al. Transmission of hepatitis B virus to gibbons by exposure to human saliva containing hepatitis B surface antigen. J Infect Dis. 1977; 135: 79 - 85.
14. Scott RM, Snitbhan R, Bancroft WH, et al. Experimental transmission of hepatitis B virus by semen and saliva. J Infect Dis 1980; 142: 67-71.
15. Bowes M.. Pathways of controlling Hepatitis A and B: Vaccination, Prevention and Treatment. American Academy of Family Physicians, 2003. Available at: www.cepis.ops-oms.org/bvsacd/cd49/hepatitis2004.pdf Accessed April 22, 2009.
16. Siebert D and Locarnini S. Hepatitis B: issues in laboratory diagnosis and vaccination. Aust Prescr 1998; 21: 72 - 5.
17. Zuckermann JN. Non-response to hepatitis B vaccines and the kinetics of anti-HBs production. Journal of Medical Virology 1996; 50: 283 - 8.
18. Zuckerman JN, Sabin C, Craig FM, et al. Immune response to a new hepatitis B vaccine in healthcare workers who had not responded to standard vaccine : randomised blind dose- response study. Br Med J 1997 ; 314: 329 - 33.
19. Ronald WE. Hepatitis B vaccine in clinical practice. New York: Taylor & Francis, 1993:301.
20. Harpaz R, MacMohan BJ, Margolis HS. Elimination of new chronic hepatitis B virus infection : results of the Alaska immunization program. J Infect Dis 2000 ; 181: 413 - 418.
21. Ni YH, Chang MH, Huang LM, et al. Hepatitis B virus infection in children and adolescence in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med 2001; 135:796 - 800.
22. Bonanni P, Pesavento G, Bechini A, et al. Impact of universal vaccination programmes on the epidemiology of hepatitis B: 10 years of experience in Italy. Vaccine 2003; 21: 685 - 691.
23. West DJ, Calandra GB. Vaccine induced immunologic memory for hepatitis B surface antigen: implication for policy on booster vaccination. Vaccine 1996; 14(11): 1019 - 1027
24. Tsebes KV, Burnett RJ, Hlungwani NP, et al. The first five years of universal hepatitis B vaccination in South Africa; evidence for elimination of HBsAg carriage in under 5-year-children. Vaccine 2001; 19: 3919 - 3926.
25. Ribeiro TM and Azevedo RS. Seroconversion of hepatitis B vaccine in infants related to the mothers serostatus in a community of Sao Jose dos Campos, state of Sao Paulo, Brazil. Clinics 2006; 61: 5.
26. Khan TM. Evaluation of immnue status against hepatitis B following Hep-B vaccination under EPI programme. 2006.
27. Craig B, Mitchell I, Anthony J, et al. Serological Hepatitis B Immunity in Vaccinated Health Care Workers. Arch Intern Med 1999; 159: 13.
28. Zeeshan. Immune response after hepatitis B vaccine in different parts of the world. BMC Infectious Diseases 2007; 7: 120.
29. Malay S, Tizer K, Lutwick LL. Current update of pediatric hepatitis vaccine use. Pediatr Clin North Am 2000; 47: 395-406.
30. Troin F. Degos F, Brechot C, et al. Randomized doses : Range study of Recombinant hepatitis B vaccine Produced in Mammalian cells and Containing the S and pre S 2 sequences. J Infect Dis 1989; 160(2): 199 - 204
31. Ukene T, Esber H, Bessette R, et al. Site of injection and response to hepatitis B vaccine. N Eng J Med 1985; 313(9): 579 -580.
32. Sharifi-Mood B, Izadi S, Salehi M, et al. Comparison of Immunogenicity of Low dose ID Hepatitis B Vaccine with Standard dose IM vaccination in Young Healthy Iranian Adults. Journal of Hepatitis Monthly 2008; 8(2): 111 - 114.
33. Craven DE, Awdeh ZL, Kunches LM, et al. Nonresponsiveness to hepatitis B vaccine in health care workers. Ann Inter Med 1986; 105: 356-360.
34. Watanabe H, Matsuchita S, Kamikawaji N, et al. Immune suppression gene on HLA-Bw54-DR4-DRw53 haplotype controls nonresponsiveness in humans to hepatitis B surface antigen via CD8+ suppressor T cell. Hum Immunol 1988; 22: 9 - 17.
35. Zucman SC, Gimenez JJ, Wambergue F, et al. Distict class II alleles determine antibody response to vaccination with hepatitis B surface antigen. Kidney International 1998; 53: 1626 - 1630.
36. Atkintson WL, Pickering LK, Schwartz B et al. General recommendations on immunization. Recommendations of the advisory committee on immunization practices (ACIP) and the American Associations of Family Physicians (AAFP). MMWR Recomm Rep 2002 ;55: 1- 35.
37. Watson JC, Hadler SC, Dykewich CA, et al. Measles, mumps and rubella: vaccine use and strategies for elimination of measles rubella and congenital rubella syndrome.
38. Border KR, Cortese MM, Iskander JK, et al. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines: recommendations of Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2006; 55: 1-34
39. CDC. Protection against viral hepatitis: recommendatios of the Immunization Practices Advisory Committee (ACIP). MMWR 1990; 39: 5 - 22.